What are the treatment options for a patient with low‑grade papillary urothelial carcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pilihan Terapi untuk Low-Grade Papillary Urothelial Carcinoma

TUR (Transurethral Resection) adalah terapi standar untuk tumor cTa low-grade, dan harus dipertimbangkan pemberian kemoterapi intravesikal dosis tunggal segera dalam 24 jam pasca-reseksi untuk mengurangi risiko rekurensi. 1

Algoritma Terapi Berdasarkan Faktor Risiko

1. Reseksi Tumor (TUR)

  • TUR lengkap adalah terapi primer untuk semua tumor cTa low-grade 1, 2
  • Reseksi harus mencakup muscularis propria dalam spesimen untuk staging yang akurat
  • Sistektomi jarang dipertimbangkan untuk lesi Ta low-grade 1

2. Terapi Intravesikal Adjuvan

Pasien Risiko Rendah (tumor soliter, kecil, tanpa riwayat rekurensi):

  • Observasi ATAU kemoterapi intravesikal dosis tunggal dalam 24 jam 1
  • Meta-analisis menunjukkan instilasi segera menurunkan rekurensi dari 48% menjadi 37% 1
  • Mitomycin C adalah agen yang paling sering digunakan 1
  • Imunoterapi (BCG) TIDAK direkomendasikan untuk kelompok ini 1

Pasien dengan Faktor Risiko Tinggi untuk Rekurensi:

Pertimbangkan faktor: ukuran tumor, jumlah tumor, kategori T, grade, CIS konkomitan, dan rekurensi sebelumnya 1

Untuk tumor multipel/besar/rekuren low-grade Ta:

  • Kemoterapi intravesikal dosis tunggal segera, diikuti dengan induksi 6 minggu kemoterapi intravesikal 1
  • Alternatif: BCG induksi dapat dipertimbangkan untuk pasien dengan tumor multipel atau rekuren 3
  • Meta-analisis menunjukkan BCG menurunkan rekurensi 24% dibanding TUR saja 3

3. Kontraindikasi Kemoterapi Intravesikal Segera

Hindari jika:

  • TUR ekstensif dilakukan
  • Perforasi kandung kemih dicurigai 1

Surveillance dan Follow-up

Protokol sistoskopi:

  • Sistoskopi pertama pada 3 bulan pasca-TUR 1, 2, 1
  • Kemudian dengan interval yang meningkat sesuai risiko rekurensi
  • Jika tidak ada rekurensi dalam tahun pertama, interval dapat diperpanjang 2

Catatan Penting:

  • Risiko progresi ke stadium lebih lanjut adalah rendah untuk tumor Ta low-grade 1, 2
  • Namun risiko rekurensi tetap tinggi (54-67% pasien mengalami minimal 1 rekurensi) 4, 5
  • Sitologi urin rutin tidak direkomendasikan untuk low-grade disease karena sensitivitas rendah 6

Pertimbangan Khusus

Untuk pasien dengan tumor rekuren low-grade:

  • Terapi intravesikal adjuvan sangat direkomendasikan 2
  • Penggunaan tembakau dan tidak menggunakan instilasi intravesikal adalah faktor risiko signifikan untuk rekurensi tinggi 4

Ablasi di klinik (office-based ablation):

  • Dapat dipertimbangkan untuk pasien dengan riwayat eksklusif Ta low-grade, ≤5 lesi papiler (≤1 cm), dan sitologi negatif 6
  • Harus disertai dengan sampling jaringan bila memungkinkan

Peringatan: Meskipun tumor low-grade memiliki prognosis baik, 8-19% pasien dapat mengalami progresi grade atau stage 5, 4, sehingga surveillance ketat tetap esensial.

Related Questions

What is the initial management for noninvasive low-grade papillary urothelial carcinoma?
What is the appropriate treatment for an 86-year-old male with newly diagnosed non-invasive low-grade papillary bladder carcinoma larger than 5 cm and no muscle involvement?
How long will a patient with a 2.5 cm low-grade papillary urothelial cancer (non-invasive) lesion, with residual neoplasm present after initial treatment and normal yearly cystoscopy and cytology results, need to undergo follow-up?
What is the recommended frequency and duration of cystoscopy (cystoscopic examination) for a 70-year-old female with a history of low-grade bladder transitional cell carcinoma (TCC)?
What adjuvant therapy is recommended after definitive surgery for a patient with papillary urothelial carcinoma of the renal pelvis staged pTa (non‑invasive, low‑grade)?
Which inhaler is comparable to Seretide (fluticasone propionate/salmeterol)?
In a patient with a second occurrence of deep vein thrombosis, when should an inferior vena cava (IVC) filter be considered?
Given a suppressed thyroid‑stimulating hormone, normal free thyroxine, and markedly elevated β‑human chorionic gonadotropin, what is the next step in management?
In a 2‑year‑7‑month‑old child with a tracheostomy who has persistent thick tracheal secretions despite twice‑daily acetylcysteine, could tolerance to the medication be responsible, and what is the appropriate management for the accompanying nasal congestion?
Can nonsteroidal anti-inflammatory drugs (NSAIDs) be used safely in elderly patients?
What is the appropriate management for a patient with accelerated hypertension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.